Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1α containing Pro564

FEBS Letters

Volumn 580, Issue 24, 2006, Pages 5718-5722

  Harada, Hiroshi ^a,b   Kizaka Kondoh, Shinae ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Caspase 3; Hypoxia; Hypoxia inducible factor 1; von Hippel Lindau

Indexed keywords

CASPASE 3; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCASPASE 3; PROLINE; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STABILITY;

AMINO ACID MOTIFS; APOPTOSIS; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROLINE; RECOMBINANT FUSION PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33749327178     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.09.025     Document Type: Article

References (25)

1. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15 (1999) 551-578
2. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 5447-5454
3. Huang L.E., Gu J., Schau M., and Bunn H.F. Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 5 (1998) 7987-7992
4. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274 (1999) 6519-6525
5. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
6. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., and Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
7. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275 (2000) 25733-25741
8. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., and Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2 (2000) 423-427
9. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 97 (2000) 10430-10435
10. Tanimoto K., Makino Y., Pereira T., and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19 (2000) 4298-4309
11. Harada H., Hiraoka M., and Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 62 (2002) 2013-2018
12. Kizaka-Kondoh S., Inoue M., Harada H., and Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 94 (2003) 1021-1028
13. Inoue M., Mukai M., Hamanaka Y., Tatsuta M., Hiraoka M., and Kizaka-Kondoh S. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int. J. Oncol. 25 (2004) 713-720
14. Harada H., Kizaka-Kondoh S., and Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol. Imaging 4 (2005) 182-193
15. Fernandes-Alnemri T., Litwack G., and Alnemri E.S. CPP32, a novel human apoptotic protein with homology toaenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem. 269 (1994) 30761-30764
16. Iliopoulos O., Kibel A., Gray S., and Kaelin Jr. W.G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1 (1995) 822-826
17. Johnson C.R., and Jarvis W.D. Caspase-9 regulation: an update. Apoptosis 9 (2004) 423-427
18. Nagarajah N.S., Vigneswaran N., and Zacharias W. Hypoxia-mediated apoptosis in oral carcinoma cells occurs via two independent pathways. Mol. Cancer 3 (2004) 38
19. Mirnezami A.H., Campbell S.J., Darley M., Primrose J.N., Johnson P.W., and Blaydes J.P. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr. Biol. 13 (2003) 1234-1239
20. Zhu Y., Mao X.O., Sun Y., Xia Z., and Greenberg D.A. p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J. Biol. Chem. 277 (2002) 22909-22914
21. Alarcon R., Koumenis C., Geyer R.K., Maki C.G., and Giaccia A.J. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 59 (1999) 6046-6051
22. Graeber T.G., Peterson J.F., Tsai M., Monica K., Fornace Jr. A.J., and Giaccia A.J. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14 (1994) 6264-6277
23. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., and Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284 (1999) 156-159
24. Rothmann T., Hengstermann A., Whitaker N.J., Scheffner M., and zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72 (1998) 9470-9478
25. Bouvet M., Bold R.J., Lee J., Evans D.B., Abbruzzese J.L., Chiao P.J., McConkey D.J., Chandra J., Chada S., Fang B., and Roth J.A. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol. 5 (1998) 681-688